MCID: GNG010
MIFTS: 32

Gangliosidosis Gm2 malady

Categories: Metabolic diseases, Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Bone diseases

Aliases & Classifications for Gangliosidosis Gm2

Aliases & Descriptions for Gangliosidosis Gm2:

Name: Gangliosidosis Gm2 12 14
Gm>2< Gangliosidosis 12
Gangliosidoses, Gm2 42

Classifications:



External Ids:

Disease Ontology 12 DOID:3321
ICD10 33 E75.0 E75.00
MeSH 42 D020143
SNOMED-CT 64 33316007
UMLS 69 C0268274

Summaries for Gangliosidosis Gm2

MalaCards based summary : Gangliosidosis Gm2, also known as gm>2< gangliosidosis, is related to tay-sachs disease and sandhoff disease, infantile, juvenile, and adult forms. An important gene associated with Gangliosidosis Gm2 is HEXA (Hexosaminidase Subunit Alpha), and among its related pathways/superpathways are Chondroitin sulfate/dermatan sulfate metabolism and Sphingolipid metabolism. The drugs Miglustat and 1-Deoxynojirimycin have been mentioned in the context of this disorder. Related phenotype is liver/biliary system.

Related Diseases for Gangliosidosis Gm2

Diseases in the Gangliosidosis Gm2 family:

Gm1-Gangliosidosis, Type I Gm1-Gangliosidosis, Type Ii
Gm1-Gangliosidosis, Type Iii Gm2-Gangliosidosis, Ab Variant
Gangliosidosis Gm1 Gm2 Gangliosidosis, 0 Variant
Gm2-Gangliosidosis, B, B1, Ab Variant

Diseases related to Gangliosidosis Gm2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 24)
id Related Disease Score Top Affiliating Genes
1 tay-sachs disease 11.3
2 sandhoff disease, infantile, juvenile, and adult forms 11.0
3 gm2-gangliosidosis, ab variant 11.0
4 seizures, benign familial infantile, 1 10.0 CTSA HEXA
5 chronic pyelonephritis 10.0 GLB1 HEXA
6 partial motor epilepsy 9.9 GLB1 HEXA
7 aggressive systemic mastocytosis 9.9 CTSA NAGA
8 fucosidosis 9.9 CTSA HEXA NAGA
9 megakaryocytic leukemia 9.9 CTSA HEXA NAGA
10 hyperinsulinemic hypoglycemia, familial, 4 9.9 CTSA HEXA NAGA
11 retinitis pigmentosa 29 9.9 CTSA NAGA
12 spina bifida occulta 9.9 CTSA GLB1
13 mononeuritis of lower limb 9.8 GLB1 HEXA HEXB
14 severe combined immunodeficiency due to ada deficiency 9.8 CTSA GLB1
15 myopia 23, autosomal recessive 9.8 CTSA GLB1 HEXA
16 malignant fibrous histiocytoma of bone 9.7 CTSA GLB1 NAGA
17 nasopharyngeal carcinoma 2 9.7 CTSA GLB1 NAGA
18 myasthenia gravis 9.7 CTSA GLB1
19 mannosidosis 9.6 CTSA GLB1 HEXA HEXB
20 striatal degeneration, autosomal dominant 9.5 ETFA GM2A HEXA HEXB HHEX MGEA5
21 dysostosis 9.4 CTSA GLB1 HEXA HEXB HHEX MGEA5
22 glioma susceptibility 4 9.3 CTSA ETFA GM2A HEXA HEXB HHEX
23 spondyloenchondrodysplasia with immune dysregulation 9.0 CTSA ETFA GLB1 GM2A HEXA HEXB
24 purpura 8.8 CTSA ETFA GLB1 GM2A HEXA HEXB

Graphical network of the top 20 diseases related to Gangliosidosis Gm2:



Diseases related to Gangliosidosis Gm2

Symptoms & Phenotypes for Gangliosidosis Gm2

MGI Mouse Phenotypes related to Gangliosidosis Gm2:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.02 CTSA GLB1 HEXA HEXB HHEX

Drugs & Therapeutics for Gangliosidosis Gm2

Drugs for Gangliosidosis Gm2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miglustat Approved Phase 4,Phase 3,Phase 2 72599-27-0 51634
2
1-Deoxynojirimycin Experimental Phase 4,Phase 3,Phase 2 19130-96-2 1374
3 Anti-HIV Agents Phase 4,Phase 3,Phase 2
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
6 Antiviral Agents Phase 4,Phase 3,Phase 2
7 Cardiac Glycosides Phase 4,Phase 3,Phase 2
8 Glycoside Hydrolase Inhibitors Phase 4,Phase 3,Phase 2
9 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
10
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
12
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
14 Alkylating Agents Phase 2, Phase 3
15 Antilymphocyte Serum Phase 2, Phase 3
16 Antineoplastic Agents, Alkylating Phase 2, Phase 3
17 Antirheumatic Agents Phase 2, Phase 3
18 Immunosuppressive Agents Phase 2, Phase 3
19 Methylprednisolone acetate Phase 2, Phase 3
20 Methylprednisolone Hemisuccinate Phase 2, Phase 3
21 Prednisolone acetate Phase 2, Phase 3
22 Prednisolone hemisuccinate Phase 2, Phase 3
23 Prednisolone phosphate Phase 2, Phase 3
24
Pyrimethamine Approved, Vet_approved Phase 1, Phase 2 58-14-0 4993
25
alemtuzumab Approved, Investigational Phase 2 216503-57-0
26
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
27
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
28
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
29
Hydroxyurea Approved Phase 2 127-07-1 3657
30
Melphalan Approved Phase 2 148-82-3 4053 460612
31
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 1, Phase 2 58-05-9 54575, 6560146 143
34 tannic acid Approved, Nutraceutical Phase 2
35 Antimalarials Phase 1, Phase 2
36 Antiparasitic Agents Phase 1, Phase 2
37 Antiprotozoal Agents Phase 1, Phase 2
38 Folic Acid Antagonists Phase 1, Phase 2
39 Vitamin B Complex Phase 1, Phase 2
40 Antifungal Agents Phase 2
41 Antimetabolites Phase 2
42 Antimetabolites, Antineoplastic Phase 2
43 Calcineurin Inhibitors Phase 2
44 Dermatologic Agents Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 2
46 Folate Nutraceutical Phase 1, Phase 2
47 Vitamin B9 Nutraceutical Phase 1, Phase 2

Interventional clinical trials:

(show all 17)
id Name Status NCT ID Phase
1 Synergistic Enteral Regimen for Treatment of the Gangliosidoses Recruiting NCT02030015 Phase 4
2 Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses Completed NCT00672022 Phase 3
3 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3
4 Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) Completed NCT01102686 Phase 1, Phase 2
5 Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis Completed NCT00418847 Phase 2
6 HSCT for High Risk Inherited Inborn Errors Completed NCT00383448 Phase 2
7 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
8 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
9 A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis Withdrawn NCT00679744 Phase 1
10 Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases Withdrawn NCT01003912 Phase 1
11 Gene Therapy for Tay-Sachs Disease Completed NCT01869270
12 Diagnostic and Screening Study of Genetic Disorders Completed NCT00006057
13 A Natural History of Late Onset Tay-Sachs Disease Recruiting NCT02851862
14 Biomarker for GM1/GM2 - Gangliosidoses Recruiting NCT02298647
15 A Natural History Study of the Gangliosidoses Recruiting NCT00668187
16 Nervous System Degeneration in Glycosphingolipid Storage Disorders Recruiting NCT00029965
17 Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. Active, not recruiting NCT01999257

Search NIH Clinical Center for Gangliosidosis Gm2

Cochrane evidence based reviews: gangliosidoses, gm2

Genetic Tests for Gangliosidosis Gm2

Anatomical Context for Gangliosidosis Gm2

Publications for Gangliosidosis Gm2

Variations for Gangliosidosis Gm2

Expression for Gangliosidosis Gm2

Search GEO for disease gene expression data for Gangliosidosis Gm2.

Pathways for Gangliosidosis Gm2

Pathways related to Gangliosidosis Gm2 according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.12 GLB1 HEXA HEXB
2
Show member pathways
11.76 CTSA GLB1 GM2A HEXA HEXB
3
Show member pathways
11.52 GLB1 HEXA HEXB
4
Show member pathways
11.34 HEXA HEXB
5 11.19 CTSA GLB1 GM2A HEXA HEXB NAGA
6
Show member pathways
11.11 HEXA HEXB NAGA
7
Show member pathways
10.94 GLB1 HEXA HEXB
8
Show member pathways
10.73 GLB1 HEXA HEXB
9 10.59 GLB1 HEXA HEXB

GO Terms for Gangliosidosis Gm2

Cellular components related to Gangliosidosis Gm2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.87 CTSA ETFA GLB1 GM2A HEXA HEXB
2 azurophil granule lumen GO:0035578 9.46 CTSA GLB1 GM2A HEXB
3 lysosome GO:0005764 9.43 CTSA GLB1 GM2A HEXA HEXB NAGA
4 azurophil granule GO:0042582 9.26 HEXA HEXB
5 lysosomal lumen GO:0043202 9.02 CTSA GLB1 GM2A HEXA HEXB

Biological processes related to Gangliosidosis Gm2 according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.76 CTSA GLB1 GM2A HEXB
2 carbohydrate metabolic process GO:0005975 9.56 GLB1 HEXA HEXB NAGA
3 metabolic process GO:0008152 9.55 GLB1 HEXA HEXB MGEA5 NAGA
4 neuromuscular process controlling balance GO:0050885 9.49 GM2A HEXB
5 lipid storage GO:0019915 9.48 GM2A HEXB
6 hyaluronan catabolic process GO:0030214 9.43 HEXA HEXB
7 chondroitin sulfate catabolic process GO:0030207 9.4 HEXA HEXB
8 oligosaccharide catabolic process GO:0009313 9.37 GM2A HEXB
9 ganglioside catabolic process GO:0006689 9.32 GM2A HEXB
10 keratan sulfate catabolic process GO:0042340 9.13 GLB1 HEXA HEXB
11 glycosphingolipid metabolic process GO:0006687 9.02 CTSA GLB1 GM2A HEXA HEXB

Molecular functions related to Gangliosidosis Gm2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.8 CTSA GLB1 GM2A HEXA HEXB MGEA5
2 enzyme activator activity GO:0008047 9.4 CTSA GM2A
3 acetylglucosaminyltransferase activity GO:0008375 9.37 HEXA HEXB
4 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004553 9.33 GLB1 HEXB NAGA
5 exo-alpha-sialidase activity GO:0004308 9.32 CTSA GLB1
6 beta-N-acetylhexosaminidase activity GO:0004563 9.13 GM2A HEXA HEXB
7 hydrolase activity, acting on glycosyl bonds GO:0016798 9.02 GLB1 HEXA HEXB MGEA5 NAGA

Sources for Gangliosidosis Gm2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....